Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
CinCor Pharma
Waltham, Massachusetts, United Statescincor.com ↗
- Ownership
- Private
- Employees
- ~19
- Development stage
- Other
01
Overview
Baxdrostat demonstrated statistically significant reductions in systolic blood pressure in treatment-resistant hypertension patients during Phase II trials. The BrigHtn trial met its primary endpoint with an average placebo-adjusted reduction of ~11 mmHg at the highest dose. Safety and tolerability were favorable. The HALO trial further confirmed efficacy and safety, supporting advancement to pivotal Phase III studies.
- Therapeutic areas
- EndocrinologyCardiovascularNephrology
- Modalities
- Small molecules (notably oral small molecule inhibitors)
- Industry
- Biotech
02
Partnerships
Exclusive worldwide license for baxdrostat remained post-acquisition by AstraZeneca
Beyond the preview
Go deeper on CinCor Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CinCor Pharma.